左室压力负荷过重诱导代谢脆弱性加重蒽环类心脏毒性
该研究在Yucatan猪中通过主动脉缩窄诱导左室压力负荷过重,4个月后给予低风险累积剂量多柔比星(每周1 mg/kg静脉注射,共5次),发现压力负荷过重心脏对蒽环类更易感,多柔比星破坏代偿机制,导致死亡率增加、LVEF下降、纤维化增加和线粒体呼吸受损。在HL-1心肌细胞中,降低能量需求的mavacamten可挽救联合应激下的细胞活力。
要点
- 左室压力负荷过重使心脏对蒽环类心脏毒性更敏感,与高能量需求状态相关。
- 低风险剂量多柔比星在压力负荷过重心脏中即可导致心功能不全和心衰。
- 针对代谢脆弱性的预防策略对接受蒽环类治疗的压力负荷过重患者迫切需要的。
核心结论
- 左室压力负荷过重通过诱导高能量需求状态增加心肌对蒽环类心脏毒性的易感性。
- 低风险剂量多柔比星在压力负荷过重心脏中破坏代偿机制,快速导致心功能障碍和心衰。
研究设计与样本
- 研究使用2月龄Yucatan猪(雌雄均含),通过主动脉缩窄术诱导左室压力负荷过重或不做手术。
- 4个月后给予低风险累积剂量多柔比星(每周1 mg/kg静脉注射,共5次)或溶剂,形成四组:健康对照、Dox、Banding、B+Dox。
- 通过心脏磁共振、磁共振波谱和混合正电子发射/计算机断层扫描评估心脏功能、结构和代谢,持续8个月。
- 研究终点分析蛋白质组学和线粒体结构与功能,并辅以体内外研究探讨能量失衡的机制作用。
主要发现
- 左室压力负荷过重增加左室质量(P < .0001)和射血分数(P = .0081),并出现代偿性代谢改变(磷酸肌酸下降,P = .022)。
- 单独低风险多柔比星改变心肌代谢(葡萄糖摄取增加,P = .014)但保留心脏功能。
- 在已有左室压力负荷过重的猪中,多柔比星增加死亡率(P < .0001 vs 所有其他组),降低左室射血分数(P < .0001),增加纤维化,并损害线粒体呼吸(P = .032)。
- 在HL-1心肌细胞中,使用mavacamten降低能量需求可挽救联合多柔比星和肥大应激下的细胞活力。
关键数值与推荐
- 低风险累积剂量多柔比星方案:每周1 mg/kg静脉注射,共5次。
- 左室压力负荷过重增加左室质量(P < .0001)和射血分数(P = .0081),磷酸肌酸下降(P = .022)。
- 单独多柔比星增加葡萄糖摄取(P = .014)。
- 压力负荷过重联合多柔比星增加死亡率(P < .0001 vs 所有其他组),降低LVEF(P < .0001),损害线粒体呼吸(P = .032)。
临床怎么用
- 对已有左室压力负荷过重(如高血压或瓣膜性心脏病)的患者,接受蒽环类治疗时需警惕心脏毒性风险增加。
- 即使使用低风险剂量蒽环类,压力负荷过重患者也可能快速出现心功能障碍和心衰,应加强监测。
- 针对代谢脆弱性的预防策略可能成为此类患者的治疗方向。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Hypertension and valvular heart disease, both associated with left ventricular (LV) pressure overload, increase the risk of anthracycline cardiotoxicity. While epidemiologically established, the underlying mechanisms remain unclear, precluding identification of therapeutic targets. METHODS: Two-month-old Yucatan pigs (males and females) underwent aortic banding to induce LV pressure overload or no operation. After 4 months, animals received a low-risk cumulative dose of doxorubicin (5 weekly 1 mg/kg intravenous injections) or vehicle, generating four groups: (i) healthy controls (no LV overload, no doxorubicin), (ii) Dox (doxorubicin, no LV overload), (iii) Banding (B: LV overload, no doxorubicin), and (iv) B + Dox (LV overload plus doxorubicin). Cardiac function, structure, and metabolism were assessed over 8 months by cardiac magnetic resonance, magnetic resonance spectroscopy, and hybrid positron emission tomography/computed tomography. At study end, proteomics and mitochondrial structure and function were analysed. Complementary in vivo and ex vivo studies examined the mechanistic role of energetic imbalance. RESULTS: LV overload increased LV mass (P < .0001) and ejection fraction (P = .0081), with compensatory metabolic changes (drop in phosphocreatine (P = .022)). Low-risk Dox alone altered myocardial metabolism (increased glucose uptake, P = .014) but preserved cardiac function. In pigs with pre-existing LV pressure overload, doxorubicin increased mortality (P < .0001 vs all other groups), reduced left ventricular ejection fraction (LVEF) (P < .0001), increased fibrosis, and impaired mitochondrial respiration (P = .032). In HL-1 cardiomyocytes, reducing energy demand with mavacamten rescued cell viability under combined doxorubicin and hypertrophic stress. CONCLUSIONS: LV pressure overload increases myocardial susceptibility to anthracycline cardiotoxicity by inducing a high-energy-demand state. Anthracycline treatment, even at a low-risk dose, disrupts compensatory mechanisms in the pressure-overloaded heart, rapidly leading to cardiac dysfunction and heart failure. Preventive strategies targeting this metabolic vulnerability are urgently needed for patients with extant LV pressure overload (e.g. hypertension or valvular heart disease) who are undergoing anthracycline therapy.
引用
- Galán-Arriola C, Pérez-Camargo D, Jorge I, et al. Anthracycline cardiotoxicity: role of metabolic vulnerability induced by cardiac pressure overload. Eur Heart J. 2026. PMID: 41528064. doi:10.1093/eurheartj/ehaf1060
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。